Sir,
We thank Dr Norris and Dr McCulloch1 for their interest in our paper2 and for their very informative comments. We fully agree with them on the issues and potential difficulties in designing a randomised controlled trial (RCT) when one of the modalities of treatment (oral propranolol) has a very high ‘success’ rate in published literature. We have highlighted this in our paper under the subheading ‘areas for future research’. We collude with the authors on the need for an RCT to further explore dosage and duration of oral propranolol therapy and to monitor adverse effects.
References
Norris JH, McCulloch PG . Reply to Spiteri Cornish and Reddy. Eye 2012; 26: 1275–1276.
Spiteri Cornish K, Reddy AR . The use of propranolol in the management of periocular capillary haemangioma-a systematic review. Eye 2011; 25: 1277–1283.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Reddy, A., Spiteri Cornish, K. Response to Dr Norris and Dr McCulloch. Eye 26, 1276 (2012). https://doi.org/10.1038/eye.2012.117
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2012.117